Fig. 1From: A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinomaTreatment schedule (21-day cycle). The initial and maintenance therapy procedures for patients with advanced ESCC. TP, paclitaxel followed by cisplatin; CR, complete response; PR, partial response; PD, progressive disease; SD, stable diseaseBack to article page